Acknowledgement
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean Ministry of Education, Science and Technology (Grant no. 2016R1D1A1B02011142) to M.S.J. and (Grant no. 2018R1D1A1B07043701) to S.B.J. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant no. RS-2023-00273615) to H.J.K. This research was supported by Learning & Academic research institution for Master's·PhD students, and Postdocs (LAMP) Program of the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education (No. RS-2023-00301938).
References
- Park SG, Ewalt KL and Kim S (2005) Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci 30, 569-574
- Han JM, Park BJ, Park SG et al (2008) AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci USA 105, 11206-11211
- Kim DG, Lee JY, Lee JH et al (2016) Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2. Cancer Res 76, 3422-3436
- Yum MK, Kang JS, Lee AE et al (2016) AIMP2 controls intestinal stem cell compartments and tumorigenesis by modulating Wnt/-catenin signaling. Cancer Res 76, 4559-4568
- Choi JW, Kim DG, Lee AE et al (2011) Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet 7, e1001351
- Mayer MP (2013) Hsp70 chaperone dynamics and molecular mechanism. Trends Biochem Sci 38, 507-514
- Park SG, Choi EC and Kim S (2010) Aminoacyl-tRNA synthetase-interacting multifunctional proteins (AIMPs): a triad for cellular homeostasis. IUBMB life 62, 296-302
- Park SG, Kang YS, Ahn YH et al (2002) Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. JBC 277, 45243-45248
- Park H, Park SG, Kim J, Ko YG and Kim S (2002) Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. Cytokine 20, 148-153
- Matschurat S, Knies UE, Person V et al (2003) Regulation of EMAP II by hypoxia. Am J Pathol 162, 93-103
- Park SG, Shin H, Shin YK et al (2005) The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. Am J Pathol 166, 387-398
- Park SG, Kang YS, Kim JY et al (2006) Hormonal activity of AIMP1/p43 for glucose homeostasis. Proc Natl Acad Sci USA103, 14913-14918
- Kim E, Kim SH, Kim S, Cho D and Kim TS (2008) AIMP1/p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability. J Immunol 180, 2894-2902
- Ko YG, Park H, Kim T et al (2001) A cofactor of tRNA synthetase, p43, is secreted to up-regulate proinflammatory genes. JBC 276, 23028-23033
- Park H, Park SG, Lee JW et al (2002) Monocyte cell adhesion induced by a human aminoacyl-tRNA synthetase-associated factor, p43: identification of the related adhesion molecules and signal pathways. J Leukoc Biol 71, 223-230
- Kim E, Kim SH, Kim S and Kim TS (2006) The novel cytokine p43 induces IL-12 production in macrophages via NF-κB activation, leading to enhanced IFN-γ production in CD4+ T cells. J Immunol 176, 256-264
- Kim JY, Kang YS, Lee JW et al (2002) p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance. Proc Natl Acad Sci USA 99, 7912-7916
- Duncan R, Bazar L, Michelotti G et al (1994) A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8, 465-480
- Kim MJ, Park BJ, Kang YS et al (2003) Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 34, 330-336
- Li X, Yang Y and Ashwell JD (2002) TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416, 345-347
- Choi JW, Kim DG, Park MC et al (2009) AIMP2 promotes TNFα-dependent apoptosis via ubiquitin-mediated degradation of TRAF2. J Cell Sci 122, 2710-2715
- Han JM, Lee MJ, Park SG et al (2006) Hierarchical network between the components of the multi-tRNA synthetase complex: implications for complex formation. JBC 281, 38663-38667
- Kim JH, Han JM and Kim S (2014) Protein-protein interactions and multi-component complexes of aminoacyl-tRNA synthetases. Aminoacyl-tRNA Synthetases in Biology and Medicine, 119-144
- Park BJ, Kang JW, Lee SW et al (2005) The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR. Cell 120, 209-221
- Kim HJ, Jeong MS and Jang SB (2020) Structural and functional roles of AIMP2 and TRAF2 in TNF-α signaling. Korean J Life Sci 30, 106-112
- Ku J, Kim R, Kim D et al (2020) Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. Commun Biol 3, 630
- Jung JY, Kim EY, Kim A et al (2017) Ratio of autoantibodies of tumor suppressor AIMP2 and its oncogenic variant is associated with clinical outcome in lung cancer. J Cancer 8, 1347
- Choi JW, Lee JW, Kim JK et al (2012) Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol 4, 164-173
- Minami Ki, Saito Y, Imamura H and Okamura A (2002) Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38, 51-57
- Chang SH, Chung YS, Hwang SK et al (2012) Lentiviral vector-mediated shRNA against AIMP2-DX2 suppresses lung cancer cell growth through blocking glucose uptake. Mol Cells 33, 553-562
- Cao Q, Zhang J and Zhang T (2018) AIMP2-DX2 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma cells. Biomed Res Int 2018, 11
- Hartl FU, Bracher A and Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475, 324-332
- Feder ME and Hofmann GE (1999) Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu Rev Physiol 61, 243-282
- Kumar S, Stokes III J, Singh UP et al (2016) Targeting Hsp70: a possible therapy for cancer. Cancer Lett 374, 156-166
- Goloudina AR, Demidov ON and Garrido C (2012) Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 325, 117-124
- Lim S, Cho HY, Kim DG et al (2020) Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development. Nat Chem Biol 16, 31-41
- Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408, 307-310
- Green DR and Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458, 1127-1130
- Riley T, Sontag E, Chen P and Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9, 402-412
- Cho HY, Jha R, Mushtaq AU, Oh SH and Jeon YH (2020) Structural insight into the interaction between p53 TAD1 and AIMP2-DX2 by NMR. Biochem Biophys Res Commun 527, 831-838
- Kim HJ, Lee HN, Jeong MS and Jang SB (2021) Oncogenic KRAS: signaling and drug resistance. Cancers 13, 5599
- Kim DG, Choi Y, Lee Y et al (2022) AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nat Commun 13, 2572
- Oh AY, Jung YS, Kim J et al (2016) Inhibiting DX2-p14/ARF interaction exerts antitumor effects in lung cancer and delays tumor progression. Cancer Res 76, 4791-4804
- Lee HS, Kim DG, Oh YS et al (2013) Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. Biochem J 454, 411-416
- Cox AD, Fesik SW, Kimmelman AC, Luo J and Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13, 828-851
- Prior IA, Lewis PD and Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72, 2457-2467
- Lee S, Kim DG, Kim K et al (2020) 2-Aminophenylpyrimidines as novel inhibitors of aminoacyl-tRNA synthetase interacting multifunctional protein 2 (AIMP2)-DX2 for lung cancer treatment. J Med Chem 63, 3908-3914
- Sivaraman A, Kim DG, Bhattarai D et al (2020) Synthesis and structure-activity relationships of arylsulfonamides as AIMP2-DX2 inhibitors for the development of a novel anticancer therapy. J Med Chem 63, 5139-5158
- Kim DG, Park CM, Huddar S, Lim S, Kim S and Lee S (2020) Anticancer activity of pyrimethamine via ubiquitin mediated degradation of AIMP2-DX2. Molecules 25, 2763
- Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer: Interdisciplinary International Journal of the American Cancer Society 80, 1046-1051
- Lau KS, Partridge EA, Grigorian A et al (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129, 123-134
- Won YS and Lee SW (2012) Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme. J Biotechnol 158, 44-49
- Kim S and Choi JW (2013) AIMP2-DX2 gene and its uses. United States Patent, Patent No. US 8431,393 B2